BR100 Decreased By (-0.54%)
BR30 Decreased By (-0.74%)
KSE100 Decreased By (-0.42%)
KSE30 Decreased By (-0.37%)
AGHA 6.62 Decreased By ▼ -0.05 (-0.75%)
BECO 4.39 Increased By ▲ 0.04 (0.92%)
BML 54.95 Decreased By ▼ -1.22 (-2.17%)
BOP 29.93 Decreased By ▼ -0.19 (-0.63%)
CNERGY 12.80 Decreased By ▼ -0.18 (-1.39%)
CSIL 5.20 Decreased By ▼ -0.11 (-2.07%)
FCCL 51.18 Decreased By ▼ -0.47 (-0.91%)
FFL 14.40 Decreased By ▼ -0.09 (-0.62%)
FNEL 1.23 Increased By ▲ 0.02 (1.65%)
KEL 6.03 Decreased By ▼ -0.03 (-0.5%)
KOSM 5.60 Decreased By ▼ -0.24 (-4.11%)
LOTCHEM 26.07 Decreased By ▼ -0.10 (-0.38%)
MLCF 89.90 Decreased By ▼ -1.33 (-1.46%)
NBP 162.53 Decreased By ▼ -1.66 (-1.01%)
NCPL 52.37 Decreased By ▼ -0.81 (-1.52%)
NPL 57.85 Decreased By ▼ -1.27 (-2.15%)
OGDC 313.00 Decreased By ▼ -0.39 (-0.12%)
PACE 9.71 Decreased By ▼ -0.06 (-0.61%)
PAEL 34.90 Decreased By ▼ -0.34 (-0.96%)
PIBTL 14.37 Decreased By ▼ -0.34 (-2.31%)
PPL 219.15 Decreased By ▼ -2.21 (-1%)
PRL 91.60 Increased By ▲ 0.38 (0.42%)
PTC 59.25 Increased By ▲ 0.06 (0.1%)
SSGC 23.37 Increased By ▲ 0.07 (0.3%)
TBL 8.65 Decreased By ▼ -0.10 (-1.14%)
TELE 7.47 Decreased By ▼ -0.14 (-1.84%)
TPL 21.32 Decreased By ▼ -0.71 (-3.22%)
TPLP 12.14 Decreased By ▼ -0.42 (-3.34%)
TREET 21.64 Decreased By ▼ -0.09 (-0.41%)
TRG 55.20 Decreased By ▼ -0.59 (-1.06%)
Business & Finance

Russia's Sputnik V developers to sue Brazilian regulator for 'false information' about their vaccine

  • The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.
  • A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.
Published Updated
By

MOSCOW: Russian developers of the Sputnik V vaccine against COVID-19 said on Thursday that they were suing Brazilian regulator Anvisa for defamation, accusing it of having knowingly spread false information without testing their product.

The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.

A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.

Sputnik V's official Twitter account on Thursday cited a Brazilian media story citing the same expert as saying that no tests had been carried out to test the Brazilian theory.

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," it said.

"Anvisa made incorrect and misleading statements without having tested the actual Sputnik V vaccine."

Comments

Comments are closed for this article.